Correction

Correction: Fish oil: what the prescriber needs to know

Leslie G Cleland, Michael J James^* and Susanna M Proudman

• * Corresponding author: Michael J James mjames@mail.rah.s.gov.au

Author Affiliations

Rheumatology Unit, Royal Adelaide Hospital, North Terrace, Adelaide, Australia

For all author emails, please log on.

Arthritis Research & Therapy 2006, 8:402 doi:10.1186/ar1981

The electronic version of this article is the complete one and can be found online at: http://arthritis-research.com/content/8/4/402

Published:

1 June 2006

© 2006 BioMed Central Ltd

Correction

It has been brought to our attention that there were a number of typographical errors in one section of our recent article [1] published in December 2005.

All corrections apply to the section entitled, 'Biochemical rationale; Eicosanoids: cyclo-oxygenase pathway'.

The second paragraph should read:

The usual substrate for the COX isozymes is the n6 LC PUFA arachidonic acid (AA; C20:4n-6). Eicosapentaenoic acid (EPA; C20:5n-3), which is present in fish oil, differs from AA only by the presence of its n3 bond (Fig. 1).

The last sentence of the third paragraph should read:

Thus, the net effect of fish oil is to reduce the production of proinflammatory and pro-thrombotic eicosanoids (PGE₂ and TXA₂, respectively) but not the vascular patency factor prostacyclin (PGI₂; Fig. 2).

Finally, the first 20-Carbon fatty acid homologue pictured in Figure 1 (C20:3 n-9) is eicosatrienoic acid, rather than oleic acid.

References